Search
Palovarotene
go.drugbank.com/drugs/DB05467Approved[L39990,L40020] It has been granted rare pediatric disease and breakthrough therapy designations from the US FDA, although a previously submitted NDA was withdrawn in August 2021 pending the resubmission … It first garnered interest as a potential treatment for emphysema but was eventually recognized as a potential novel therapy for patients with FOP.
Erdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigational[L5956, L5959] At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for
Artenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalIt was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim. … Artemisinin combination therapy is highly effective against malaria and stongly recommended by the World Health Organization [L1156].
Vamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigationaland the most common form of muscular dystrophy in the United States. … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.
Categories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, PlainHuman botulinum neurotoxin A/B immune globulin
go.drugbank.com/drugs/DB14115Approved[L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism. … [L39834] It is produced and distributed by the Calfornia Department of Public Health's Infant Botulism Treatment and Prevention Program[L39829] and comprises IgG antibodies derived from pooled adult plasma
Ardeparin
go.drugbank.com/drugs/DB00407ApprovedWithdrawnNormiflo was withdrawn from the US market in March 2000. … Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis.
Acetrizoic acid
go.drugbank.com/drugs/DB09347ApprovedWithdrawn[A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978.
Categories: Compounds used in a research, industrial, or household settingBromocriptine
go.drugbank.com/drugs/DB01200ApprovedInvestigationalWithdrawnIn 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological lactation after finding that bromocriptine was not shown to be safe for use. … [L43942,L43947] It continues to be used for the indications mentioned above.
Categories: Heterocyclic Compounds with 4 or More RingsNefazodone
go.drugbank.com/drugs/DB01149ApprovedWithdrawnOn May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. … Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to
Categories: Antidepressive Agents Indicated for DepressionEdoxudine
go.drugbank.com/drugs/DB13421ApprovedWithdrawn[A32643] It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992. This medication was later discontinued from the market in 1998.[L1113] … It was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus.